Decitabine, a new star in epigenetic therapy: The clinical application and biological mechanism in solid tumors

Cancer Letters

Volumn 354, Issue 1, 2014, Pages 12-20

  Nie, Jing ^a   Liu, Lin ^a   Li, Xiang ^a   Han, Weidong ^a  

^a CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Decitabine; Demethylating drug; Drug sensitivity; Tumor therapy

Indexed keywords

5 AZA 2' DEOXYCYTIDINE; BREAST CANCER RESISTANCE PROTEIN; CISPLATIN; DNA; EPIDERMAL GROWTH FACTOR RECEPTOR; MULTIDRUG RESISTANCE PROTEIN 1; TUMOR MARKER; ANTINEOPLASTIC ANTIMETABOLITE; AZACITIDINE; DRUG DERIVATIVE;

ACUTE GRANULOCYTIC LEUKEMIA; CANCER PROGNOSIS; COLORECTAL CANCER; CONTROLLED STUDY; DNA METHYLATION; DNA REPAIR; DRUG MECHANISM; EPIGENETICS; HEMATOLOGIC MALIGNANCY; HUMAN; IMMUNE RESPONSE; LUNG CANCER; MOLECULAR MECHANICS; MOLECULARLY TARGETED THERAPY; MYELODYSPLASTIC SYNDROME; OVARY CANCER; SHORT SURVEY; SOLID TUMOR; CANCER THERAPY; CHEMISTRY; CLINICAL TRIAL (TOPIC); DEMETHYLATING DRUG; DRUG EFFECT; DRUG SENSITIVITY; GENETIC EPIGENESIS; GENETICS; NEOPLASM; PROGNOSIS; REVIEW;

DECITABINE; DEMETHYLATING DRUG; DRUG SENSITIVITY; TUMOR THERAPY;

ANTIMETABOLITES, ANTINEOPLASTIC; AZACITIDINE; CLINICAL TRIALS AS TOPIC; DNA METHYLATION; EPIGENESIS, GENETIC; HUMANS; NEOPLASMS; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL;

EID: 84910021131     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2014.08.010     Document Type: Review

References (49)

1. Esteller M., Corn P.G., Baylin S.B., Herman J.G. A gene hypermethylation profile of human cancer. Cancer Res 2001, 61:3225-3229.
2. Oki Y., Aoki E., Issa J.P. Decitabine-bedside to bench. Crit. Rev. Oncol. Hematol 2007, 61:140-152.
3. Issa J.P. Decitabine. Curr. Opin. Oncol 2003, 15:446-451.
4. Adair S.J., Hogan K.T. Treatment of ovarian cancer cell lines with 5-aza-2'-deoxycytidine upregulates the expression of cancer-testis antigens and class I major histocompatibility complex-encoded molecules. Cancer Immunol. Immunother 2009, 58:589-601.
5. Vijayaraghavalu S., Dermawan J.K., Cheriyath V., Labhasetwar V. Highly synergistic effect of sequential treatment with epigenetic and anticancer drugs to overcome drug resistance in breast cancer cells is mediated via activation of p21 gene expression leading to G2/M cycle arrest. Mol. Pharm 2013, 10:337-352.
6. Zeller C., Dai W., Steele N.L., Siddiq A., Walley A.J., Wilhelm-Benartzi C.S., et al. Candidate DNA methylation drivers of acquired cisplatin resistance in ovarian cancer identified by methylome and expression profiling. Oncogene 2012, 31:4567-4576.
7. Issa J.P., Garcia-Manero G., Giles F.J., Mannari R., Thomas D., Faderl S., et al. Phase 1 study of low-dose prolonged exposure schedules of the hypomethylating agent 5-aza-2'-deoxycytidine (decitabine) in hematopoietic malignancies. Blood 2004, 103:1635-1640.
8. Wijermans P., Lubbert M., Verhoef G., Bosly A., Ravoet C., Andre M., et al. Low-dose 5-aza-2'-deoxycytidine, a DNA hypomethylating agent, for the treatment of high-risk myelodysplastic syndrome: a multicenter phase II study in elderly patients. J. Clin. Oncol 2000, 18:956-962.
9. Chang X., Monitto C.L., Demokan S., Kim M.S., Chang S.S., Zhong X., et al. Identification of hypermethylated genes associated with cisplatin resistance in human cancers. Cancer Res 2010, 70:2870-2879.
10. Johnstone R.W., Ruefli A.A., Lowe S.W. Apoptosis: a link between cancer genetics and chemotherapy. Cell 2002, 108:153-164.
11. Luqmani Y.A. Mechanisms of drug resistance in cancer chemotherapy. Med. Princ. Pract 2005, 14(Suppl. 1):35-48.
12. Gifford G., Paul J., Vasey P.A., Kaye S.B., Brown R. The acquisition of hMLH1 methylation in plasma DNA after chemotherapy predicts poor survival for ovarian cancer patients. Clin. Cancer Res 2004, 10:4420-4426.
13. Plumb J.A., Strathdee G., Sludden J., Kaye S.B., Brown R. Reversal of drug resistance in human tumor xenografts by 2'-deoxy-5-azacytidine-induced demethylation of the hMLH1 gene promoter. Cancer Res 2000, 60:6039-6044.
14. George R.E., Lahti J.M., Adamson P.C., Zhu K., Finkelstein D., Ingle A.M., et al. Phase I study of decitabine with doxorubicin and cyclophosphamide in children with neuroblastoma and other solid tumors: a Children's Oncology Group study. Pediatr. Blood Cancer 2010, 55:629-638.
15. Dean M. ABC transporters, drug resistance, and cancer stem cells. J. Mammary Gland Biol. Neoplasia 2009, 14:3-9.
16. Dean M., Fojo T., Bates S. Tumour stem cells and drug resistance. Nat. Rev. Cancer 2005, 5:275-284.
17. Stewart D.J., Issa J.P., Kurzrock R., Nunez M.I., Jelinek J., Hong D., et al. Wistuba, II, decitabine effect on tumor global DNA methylation and other parameters in a phase I trial in refractory solid tumors and lymphomas. Clin. Cancer Res 2009, 15:3881-3888.
18. Scartozzi M., Bearzi I., Mandolesi A., Giampieri R., Faloppi L., Galizia E., et al. Epidermal growth factor receptor (EGFR) gene promoter methylation and cetuximab treatment in colorectal cancer patients. Br. J. Cancer 2011, 104:1786-1790.
19. Garrido-Laguna I., McGregor K.A., Wade M., Weis J., Gilcrease W., Burr L., et al. A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer. Invest. New Drugs 2013, 31:1257-1264.
20. Juergens R.A., Wrangle J., Vendetti F.P., Murphy S.C., Zhao M., Coleman B., et al. Combination epigenetic therapy has efficacy in patients with refractory advanced non-small cell lung cancer. Cancer Discov 2011, 1:598-607.
21. Tsai H.C., Li H., Van Neste L., Cai Y., Robert C., Rassool F.V., et al. Transient low doses of DNA-demethylating agents exert durable antitumor effects on hematological and epithelial tumor cells. Cancer Cell 2012, 21:430-446.
22. Biswal B.K., Beyrouthy M.J., Hever-Jardine M.P., Armstrong D., Tomlinson C.R., Christensen B.C., et al. Acute hypersensitivity of pluripotent testicular cancer-derived embryonal carcinoma to low-dose 5-aza deoxycytidine is associated with global DNA Damage-associated p53 activation, anti-pluripotency and DNA demethylation. PLoS ONE 2012, 7:e53003.
23. Liu M.X., Siu M.K., Liu S.S., Yam J.W., Ngan H.Y., Chan D.W. Epigenetic silencing of microRNA-199b-5p is associated with acquired chemoresistance via activation of JAG1-Notch1 signaling in ovarian cancer. Oncotarget 2014, 5:944-958.
24. Fonsatti E., Nicolay H.J., Sigalotti L., Calabro L., Pezzani L., Colizzi F., et al. Functional up-regulation of human leukocyte antigen class I antigens expression by 5-aza-2'-deoxycytidine in cutaneous melanoma: immunotherapeutic implications. Clin. Cancer Res 2007, 13:3333-3338.
25. N.Cancer Genome Atlas Research Comprehensive genomic characterization of squamous cell lung cancers. Nature 2012, 489:519-525.
26. Challa-Malladi M., Lieu Y.K., Califano O., Holmes A.B., Bhagat G., Murty V.V., et al. Combined genetic inactivation of beta2-microglobulin and CD58 reveals frequent escape from immune recognition in diffuse large B cell lymphoma. Cancer Cell 2011, 20:728-740.
27. Wrangle J., Wang W., Koch A., Easwaran H., Mohammad H.P., Vendetti F., et al. Alterations of immune response of non-small cell lung cancer with azacytidine. Oncotarget 2013, 4:2067-2079.
28. Li Q., Tainsky M.A. Epigenetic silencing of IRF7 and/or IRF5 in lung cancer cells leads to increased sensitivity to oncolytic viruses. PLoS ONE 2011, 6:e28683.
29. Chappell C., Beard C., Altman J., Jaenisch R., Jacob J. DNA methylation by DNA methyltransferase 1 is critical for effector CD8 T cell expansion. J. Immunol 2006, 176:4562-4572.
30. Stubig T., Badbaran A., Luetkens T., Hildebrandt Y., Atanackovic D., Binder T.M., et al. 5-Azacytidine promotes an inhibitory T-cell phenotype and impairs immune mediated antileukemic activity. Mediators Inflamm 2014, 2014:418292.
31. Topalian S.L., Hodi F.S., Brahmer J.R., Gettinger S.N., Smith D.C., McDermott D.F., et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N. Engl. J. Med 2012, 366:2443-2454.
32. Aparicio A., Eads C.A., Leong L.A., Laird P.W., Newman E.M., Synold T.W., et al. Phase I trial of continuous infusion 5-aza-2'-deoxycytidine. Cancer Chemother. Pharmacol 2003, 51:231-239.
33. Samlowski W.E., Leachman S.A., Wade M., Cassidy P., Porter-Gill P., Busby L., et al. Evaluation of a 7-day continuous intravenous infusion of decitabine: inhibition of promoter-specific and global genomic DNA methylation. J. Clin. Oncol 2005, 23:3897-3905.
34. Appleton K., Mackay H.J., Judson I., Plumb J.A., McCormick C., Strathdee G., et al. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. J. Clin. Oncol 2007, 25:4603-4609.
35. Fan H., Lu X., Wang X., Liu Y., Guo B., Zhang Y., et al. Low-dose decitabine-based chemoimmunotherapy for patients with refractory advanced solid tumors: a phase I/II report. J. Immunol. Res 2014, 2014. 371087.
36. Stathis A., Hotte S.J., Chen E.X., Hirte H.W., Oza A.M., Moretto P., et al. Phase I study of decitabine in combination with vorinostat in patients with advanced solid tumors and non-Hodgkin's lymphomas. Clin. Cancer Res 2011, 17:1582-1590.
37. Cannistra S.A. Cancer of the ovary. N. Engl. J. Med 2004, 351:2519-2529.
38. Fang F., Balch C., Schilder J., Breen T., Zhang S., Shen C., et al. A phase 1 and pharmacodynamic study of decitabine in combination with carboplatin in patients with recurrent, platinum-resistant, epithelial ovarian cancer. Cancer 2010, 116:4043-4053.
39. Matei D.E., Nephew K.P. Epigenetic therapies for chemoresensitization of epithelial ovarian cancer. Gynecol. Oncol 2010, 116:195-201.
40. Matei D., Fang F., Shen C., Schilder J., Arnold A., Zeng Y., et al. Epigenetic resensitization to platinum in ovarian cancer. Cancer Res 2012, 72:2197-2205.
41. Chu B.F., Karpenko M.J., Liu Z., Aimiuwu J., Villalona-Calero M.A., Chan K.K., et al. Phase I study of 5-aza-2'-deoxycytidine in combination with valproic acid in non-small-cell lung cancer. Cancer Chemother. Pharmacol 2013, 71:115-121.
42. Schrump D.S., Fischette M.R., Nguyen D.M., Zhao M., Li X., Kunst T.F., et al. Phase I study of decitabine-mediated gene expression in patients with cancers involving the lungs, esophagus, or pleura. Clin. Cancer Res 2006, 12:5777-5785.
43. Kwong J., Lee J.Y., Wong K.K., Zhou X., Wong D.T., Lo K.W., et al. Candidate tumor-suppressor gene DLEC1 is frequently downregulated by promoter hypermethylation and histone hypoacetylation in human epithelial ovarian cancer. Neoplasia 2006, 8:268-278.
44. Sellar G.C., Watt K.P., Rabiasz G.J., Stronach E.A., Li L., Miller E.P., et al. OPCML at 11q25 is epigenetically inactivated and has tumor-suppressor function in epithelial ovarian cancer. Nat. Genet 2003, 34:337-343.
45. Ibanez de Caceres I., Battagli C., Esteller M., Herman J.G., Dulaimi E., Edelson M.I., et al. Tumor cell-specific BRCA1 and RASSF1A hypermethylation in serum, plasma, and peritoneal fluid from ovarian cancer patients. Cancer Res 2004, 64:6476-6481.
46. Momparler R.L., Bouffard D.Y., Momparler L.F., Dionne J., Belanger K., Ayoub J. Pilot phase I-II study on 5-aza-2'-deoxycytidine (decitabine) in patients with metastatic lung cancer. Anticancer Drugs 1997, 8:358-368.
47. Aparicio A., Weber J.S. Review of the clinical experience with 5-azacytidine and 5-aza-2'-deoxycytidine in solid tumors. Curr. Opin. Investig. Drugs 2002, 3:627-633.
48. Pohlmann P., DiLeone L.P., Cancella A.I., Caldas A.P., Dal Lago L., Campos O., et al. Phase II trial of cisplatin plus decitabine, a new DNA hypomethylating agent, in patients with advanced squamous cell carcinoma of the cervix. Am. J. Clin. Oncol 2002, 25:496-501.
49. N.Cancer Genome Atlas Comprehensive molecular characterization of human colon and rectal cancer. Nature 2012, 487:330-337.